Skip to content

boldscience

our science

From clinical potential to meaningful therapies—Ovid Therapeutics is developing lifechanging therapies based on our deep understanding of key biological pathways and their central role in rare neurological diseases. We seek to develop medicines using novel and clinically relevant endpoints, to capture the real-world ways patients benefit from addressing underlying disorder pathology.

CDKL5 deficiency disorder (CDD)
Chromosome 15q Duplication syndrome (Sup15q)
Dravet syndrome (DS)
Lennox-Gastaut syndrome (LGS)

Cause:
Genetic mutation: CDKL5 gene on X chromosome

Age of onset:
Birth to 3 months old

Prevalence:
• 1:40,000 to 1 in 60,000
• Mainly affects females

Symptoms:
• Extended, difficult seizures and periods of
repeated seizing
• Atypical heartbeat (hypsarrhythmia)
• Repetitive hand movements
• Decreased muscle tone (hypotonia)

FDA-approved Therapies:
None

Cause:
Genetic mutation: duplication on chromosome 15

Age of onset:
6 months old to 9 years old

Prevalence:
• 1 in 30,000

Symptoms
• Motor skill delays
• Autism spectrum disorder
• Anxiety disorders
• Progressive infantile spasms
• Decreased muscle tone (hypotonia)

FDA-approved Therapies:
None

Cause:
Primarily genetic mutation: 80% have mutation in Scn1a gene

Age of onset:
Birth to 1 year old

Prevalence:
• 1 in 15,000 to 1 in 21,000

Symptoms
• Seizures: prolonged focial progressing to
convulsive tonic-clonic
• Developmental delays

FDA-approved Therapies:
• Anticonvulsants (stripentol)
• Epidiolex® (cannabidiol)

Cause:
Multiple: includes genetic mutations, fetal/infant injury before/after birth

Age of onset:
2 to 5 years old

Prevalence:
• 1 in 11,000
• More common in males

Symptoms
• Multiple types of seizures, including drop
• Intellectual disabilities (with psychiatric comorbidities)

FDA-approved Therapies:
None

Calling all bold researchers!

At Ovid, we know it takes a committed team to get breakthrough treatments into the hands of those who truly need them. Collaboration is critical in bringing impactful medicines to those who need it most. We seek like-minded potential partners driven to produce clinically impactful work for rare disease individuals and families. If you are a researcher, represent an academic medical center interested in collaborating or are interested in submitting an investigator-initiated trial (ITT), please contact us at clinical@ovidrx.com.